"C20H15ClN4"^^ . . "PTK787"^^ . "N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamineSNNCI" . "Vatalanib"^^ . "FDA"^^ . "CGP-79787CNNCI" . "VatalanibPTNCI" . "5DX9U76296"^^ . "VATALANIBPTFDA5DX9U76296" . "PTK787/ZK 222584PTNCI-GLOSSCDR0000046711" . "C0912586"^^ . "C1868"^^ . "VHL-related hemangioblastoma; refractory or recurrent metastatic colon or rectal cancer; unresectable malignant mesothelioma; primary or secondary myelodysplastic syndromes."^^ . . . . . . "ZK-232934CNNCI" . . "43530"^^ . "Organic Chemical"^^ . "212141-54-3"^^ . "A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and VEGF receptor kinase inhibitors.NCI-GLOSS" . "vatalanibPTNCI-GLOSSCDR0000390321" . . "Vatalanib"^^ . "43530"^^ . "Pharmacologic Substance"^^ . "719335"^^ . "An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.NCI" .